Status: Recruiting
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype
Participants needed: 400
Trial details
Phase: Phase 3Age: 12+Biological sex: AllType: InterventionalSponsor: Guangdong Hengrui Pharmaceutical Co., LtdUpdated: Dec 10, 2025Locations: 1
Eligibility criteria
At least 12 years of age [+11]
With other condition that could lead to elevated eosinophils [+18]